Comrise logo
Comrise Icons
Comrise Icons
English

Comrise Listed as One of 2021’s Top 10 Foreign Enterprises in China’s Headhunting Industry

November 24, 2021

Comrise Listed as One of 2021’s Top 10 Foreign Enterprises in China’s Headhunting Industry

In mid-November, TopHR released the “2021 China headhunting industry ranking”. The list recognized Comrise as a top foreign enterprise in China’s Headhunting Industry.

TopHR, China’s leading third-party media platform for human resources, has launched the “China headhunting industry ranking” for seven consecutive years.

The annual list is investigated and analyzed from multiple dimensions. These dimensions include industry advantages, business scope, operating revenue, number of customers, per unit yield of consultants, service reputation and more.

Comrise Listed as One of 2021’s Top 10 Foreign Enterprises in China's Headhunting Industry

About Comrise 

At Comrise, we offer customized solutions that are simplified for full-time, part-time, direct-hire, contract, and permanent talent for all of your business needs.  For over 35 years, we have delighted our customers by focusing on customer satisfaction, innovation, and flexible workforce solutions!

To learn more about our Cross-Border Services and how we can help your organization win, check out our LinkedIn and contact us today!

Related Posts

Major Reforms in German Labor Law for 2025

July 14, 2025

Germany’s 2025 labor law reforms bring sweeping changes—from digital contracts to adjusted social security contributions, minimum wage hikes to tightened parental benefits. This article breaks down key updates to help...

The $15 Billion Biotech War: How a U.S. Report Is Redefining Global Tech Dominance

July 7, 2025

A “Top Priority” White House Report Is Quietly Rewriting the Rules of Global Tech Competition. In April 2025, the U.S. National Security Commission on Emerging Biotechnology (NSCEB) submitted a landmark...

China's Innovative Drugs Go Global: From Followers to Game Changers

July 7, 2025

Frequent FIC/BIC deals, accelerated domestic regulation, and growing international attention—a clear trend is emerging: China’s innovative drugs are no longer followers but a significant variable in the global pharmaceutical value...

Comrise logo
Facebook-f Instagram Twitter Linkedin-in
All Rights Reserved Comrise 2020 | Website Built by Simplicity Design and Marketing | Data Privacy Policy | Terms & Conditions